[go: up one dir, main page]

MX2019013279A - Metodos de tratamiento del sindrome de doose utilizando fenfluramina. - Google Patents

Metodos de tratamiento del sindrome de doose utilizando fenfluramina.

Info

Publication number
MX2019013279A
MX2019013279A MX2019013279A MX2019013279A MX2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A MX 2019013279 A MX2019013279 A MX 2019013279A
Authority
MX
Mexico
Prior art keywords
doose syndrome
fenfluramine
treating
methods
patient
Prior art date
Application number
MX2019013279A
Other languages
English (en)
Inventor
Boyd Brooks
J Farr Stephen
Galer Bradley
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of MX2019013279A publication Critical patent/MX2019013279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar y/o prevenir los síntomas del síndrome de Doose en un paciente tal como un paciente diagnosticado previamente con el síndrome de Doose, administrando una dosis efectiva de fenfluramina o su sal farmacéuticamente aceptable a ese paciente. Los pacientes con síndrome de Doose se tratan con una dosis preferida de menos de aproximadamente 10.0 a aproximadamente 0.01 mg/kg/día.
MX2019013279A 2017-05-09 2018-05-04 Metodos de tratamiento del sindrome de doose utilizando fenfluramina. MX2019013279A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503638P 2017-05-09 2017-05-09
US201762581375P 2017-11-03 2017-11-03
PCT/GB2018/051210 WO2018206924A1 (en) 2017-05-09 2018-05-04 Methods of treating doose syndrome using fenfluramine

Publications (1)

Publication Number Publication Date
MX2019013279A true MX2019013279A (es) 2020-01-15

Family

ID=62148410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013279A MX2019013279A (es) 2017-05-09 2018-05-04 Metodos de tratamiento del sindrome de doose utilizando fenfluramina.

Country Status (12)

Country Link
US (2) US20200170965A1 (es)
EP (1) EP3634392A1 (es)
JP (2) JP2020519594A (es)
KR (1) KR20190142364A (es)
CN (1) CN110891558A (es)
AU (1) AU2018265353A1 (es)
BR (1) BR112019023483A2 (es)
CA (1) CA3062247A1 (es)
MX (1) MX2019013279A (es)
TW (1) TW201900158A (es)
WO (1) WO2018206924A1 (es)
ZA (1) ZA201907168B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
PT3393655T (pt) 2015-12-22 2021-02-23 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
ES3029536T3 (en) 2016-08-24 2025-06-24 Zogenix International Ltd Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
GB2594767B (en) 2017-08-25 2022-06-22 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
WO2010015029A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
KR102615486B1 (ko) * 2015-08-24 2023-12-19 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법

Also Published As

Publication number Publication date
CA3062247A1 (en) 2018-11-15
JP2023071832A (ja) 2023-05-23
JP2020519594A (ja) 2020-07-02
RU2019135674A (ru) 2021-06-09
US20220226262A1 (en) 2022-07-21
RU2019135674A3 (es) 2021-08-31
EP3634392A1 (en) 2020-04-15
TW201900158A (zh) 2019-01-01
BR112019023483A2 (pt) 2020-06-30
AU2018265353A1 (en) 2019-11-21
KR20190142364A (ko) 2019-12-26
WO2018206924A1 (en) 2018-11-15
CN110891558A (zh) 2020-03-17
US20200170965A1 (en) 2020-06-04
ZA201907168B (en) 2021-01-27

Similar Documents

Publication Publication Date Title
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2021002321A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2021002322A (es) Nuevos metodos.
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
ZA202000028B (en) Use of vibegron to treat overactive bladder
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EA202193276A1 (ru) Способы лечения холангиокарциномы
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.